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Abstract
Bismuth has gained attention in preclinical research because of its ability to attenuate 
X-rays and high biocompatibility, which make it an excellent element for use in a biomed-
ical agent or in radiation shielding. Developments in the synthesis of elemental bismuth 
nano- and microparticles, their X-radiation interactions, and their biological interactions 
will be reviewed in this chapter. The chapter will pay special focus to emerging medical 
applications of elemental bismuth nano- and microparticles, including the possibility of 
targeted molecular X-ray imaging, photo-thermal and X-radiation dose enhancing thera-
pies for cancer treatment, and the construction of flexible radiation shielding materials 
and X-ray opaque devices.
Keywords: bismuth nanomaterial, contrast agent, therapeutic, X-ray imaging, X-ray 
shielding
1. Introduction to X-ray attenuating materials for medical 
applications
Ionizing radiation is used in many minimally invasive surgical techniques and diagnostic 
tests and is an invaluable tool for both its therapeutic and diagnostic benefit. Therapeutic radi-
ation is used to treat cancers by delivering high doses of ionizing radiation to solid tumors, 
and diagnostic radiation imaging has been adapted for use in a broad range of medical dis-
ciplines including 2D conventional X-ray, 3D Computed Tomography (CT), and real-time 
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X-ray fluoroscopy imaging. Furthermore, interventional radiology has become its own medi-
cal specialty, and in many cases, constitutes an entire department within a modern hospital. 
Consequently, new materials to be used as X-ray contrast agents (XCAs), X-ray therapeu-
tics, and in radiation shielding garments, have become an intensifying subject of materials 
research and development.
The X-ray attenuating and shielding properties of a given material are a function of the atomic 
number, density, and electron configuration of the interacting material. Neglecting K-edge 
effects, the general equation for the X-ray attenuation coefficient (μ) of an element is described 
in Eq. (1), where Z is atomic number, A is atomic mass, ρ is density, and E is the incident 
photon energy [1].
  μ =   𝜌Z 4  ____
 AE 3  (1)
However, X-ray radiation interacts with materials not only through scattering, but also by 
the photoelectric effect, which occurs at quantized energies characteristic of the atoms pres-
ent. Thus, a general relationship between atomic number or density and X-ray attenuation 
is confounded by K-edge effects, where the K-edge is the energy of electrons in the K-shell 
with principle quantum number equal to 1. When an incident X-ray is at this energy (e.g., 
90 keV for bismuth), it has a high probability of being absorbed, which results in a sharp 
increase in attenuation of incident photons. Furthermore, diagnostic X-ray imaging is typi-
cally performed with an X-ray tube voltage between 10 and 150 kVp, dependent on anatomi-
cal characteristics such as specimen thickness, and utilizes an energetically broad range of 
X-ray photons (Figure 1A) [2].
Including both scattering and photoelectric effects, plots of the calculated (i.e., theoretical) 
mass attenuation as a function of X-ray tube voltage are shown in Figure 1B for tungsten, 
lead and bismuth, where it can be seen that lead and bismuth have fairly similar X-ray atten-
uation per unit density over the majority of the incident photon range. In contrast, tungsten 
Figure 1. (A) The relative X-ray photon flux produced from a typical medical X-ray tube as a function of the X-ray tube 
voltage (kVp) after aluminum filtering, which removes lower energy X-rays. (B) The mass attenuation coefficient (μ/ρ) 
for bismuth, lead, and tungsten is shown as a function of X-ray photon energy (keV).
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has a lower mass attenuation than lead or bismuth, except in the range of 70–88 keV, where 
the K-edge effect increases the attenuation. However, keeping in mind that the incident 
photon flux of a medical X-ray instrument is polychromatic and dependent on the X-ray 
tube voltage, predicting quantitative contrast for compositionally different attenuating 
materials used under different instrumental conditions is difficult. Nonetheless, it is gener-
ally true that high Z, dense materials will attenuate X-rays to a greater extent relative to 
low Z, sparse materials, which makes inorganic nanoparticles attractive as X-ray imaging 
agents and shielding materials. Nanoparticles of elements such as tungsten (Z = 74), gold 
(Z = 79), lead (Z = 82) and bismuth (Z = 83), as well as compounds of these elements, have 
been considered attractive for this purpose and are the focus of much materials research 
in this field.
2. Inorganic nanoparticles as biomedical X-ray contrast and 
therapeutic agents
2.1. Challenges for developing biomedical X-ray-interacting agents
A multitude of challenges must be considered when designing a targeted X-ray-interacting 
agent for in vivo use. This includes how it will selectively and specifically identify its biologi-
cal target, the dose required to attain X-ray contrast or therapeutic effect, how it will avoid 
immune response, and possible toxicity.
In terms of the dose required to achieve X-ray contrast, the goal of a targeted XCA for use in 
CT imaging is to raise the attenuation of a specific biological tissue type (i.e., a solid tumor) 
by elevating its average atomic number. CT signal strength is measured in Hounsfield Units 
(HU), where the signal strength of air is designated as −1000 HU and water as 0 HU; the 
quantitative contrast of an XCA is evaluated in terms of HU per mM (HU/mM) of the agent or 
attenuating atom. In a 3D reconstructed CT image, each three-dimensional voxel is assigned 
an HU value indicating its X-ray attenuation. Adjacent tissues can be differentiated by CT 
when the HU difference between them is at least three times greater than the background 
noise intensity [3]. Without artificial contrast, bones are clearly visible, but adjacent soft tis-
sues must have substantially different densities to be distinguished.
Clinically available, small molecule XCAs (Figure 2), such as iopromide, iohexol, and 
iobitridol, use iodine (Z = 53) to increase the average atomic number of a tissue, and con-
sequentially its HU value. These agents are limited to systemic imaging, as opposed to tar-
geted imaging, since they are hampered by rapid kidney clearance from the bloodstream and 
a small number (<10) of high Z atoms per molecule. The quick renal clearance means that 
a radiologist must image a patient with precise timing relative to contrast agent injection. 
Additionally, long exposure times are commonly required for CT imaging, necessitating that 
the agent be delivered continuously during the procedure to ensure adequate contrast; this 
extended administration can result in kidney damage [4]. Furthermore, solutions of these 
agents are generally highly viscous at concentrations sufficient to give rise to contrast, result-
ing from the fact that CT imaging is poorly sensitive to contrast agent detection.
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The limitations of current small molecule imaging agents drive the development of new 
XCAs that can deliver greater per unit contrast to specified biological targets, with longer 
blood circulation half-lives and less viscous agent doses. Thus, to overcome the high limit of 
detection of current, small molecule imaging agents and the low sensitivity of CT imaging, 
nanoparticles carrying thousands or millions of high Z atoms (Figure 3) may provide the req-
uisite advantage and enable targeted CT imaging. So far, a variety of inorganic nanoparticles 
have been evaluated as potential X-ray attenuating agents, as further discussed in Section 2.2.
In terms of biological fate and toxicology, the bio-distribution and pharmacokinetics of inor-
ganic nanoparticles is a complex topic. For the last decade, the enhanced permeation and 
retention effect (EPR) has been cited as a reason for nanoparticle accumulation in tumor tis-
sues, a theory that is supported by multiple observations using a variety of types of nanoparti-
cles. The EPR effect is explained by the large size of fenestrations in tumor vasculature, which 
are believed to enable uptake of particles as large as 200 nm in diameter. However, the EPR 
effect has been disputed, since many of the in vivo demonstrations of it have been performed 
in mice with transfected tumors, which are not necessarily reflective of naturally-occurring 
Figure 2. Three examples of iodine-based contrast agents currently in clinical use.
Figure 3. Representation of a targeted Bi NP XCA containing thousands or millions of high-Z bismuth atoms (e.g., a 
50 nm Bi NP contains ~1 million Bi atoms). The targeting vector is chosen so that it specifically recognizes a biological 
receptor, such as a cell surface protein.
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human tumors due to their disproportionately large sizes. Further, even in such dispropor-
tionately large tumors, low nanoparticle accumulation rates are commonly observed [5, 6].
Despite the absence of well-established principles concerning nanoparticle bio-distribution 
and fate, several empirically observed trends have been noted and are commonly considered 
in the design of biomedical agents. When considering the clearance strategy of an intravascu-
larly administered nanoparticle agent, particle size is perhaps the most important variable. It 
is generally accepted that nanoparticles smaller than 6 nm can be removed by filtration though 
the kidneys, similar to many small molecules and ions. However, nanoparticles of all sizes can 
be eliminated by the mononuclear phagocyte system (MPS), a wide-ranging group of cell types 
that are capable of removing foreign objects from the bloodstream. This occurs due to the accu-
mulation of proteins on the nanoparticle surfaces, which results in identification, uptake, and 
ultimately clearance by phagocytes. Other factors, including shape, surface charge, and surface 
chemical functionalities are also important determinants in the identification of nanomaterials by 
the MPS [7]. To date, a large number of nanoparticles that have been tested in pre-clinical settings 
have been observed to be sequestered from circulation by the MPS, never reaching their intended 
target. However, nanoparticles with an electrically neutral surface, and in particular those with 
polyethylene glycol (PEG) surface coatings, have been shown to accumulate proteins to a lesser 
extent, which slows MPS recognition and thus enables particles to stay in circulation longer.
2.2. Development of early nanoparticle X-ray contrast agents
The first demonstration of nanoparticles as XCAs was published by Hainfeld et al. [8], where 
ultra-small gold nanoparticles (Au NPs, ~2 nm) were imaged in an in vivo mouse model. The 
result was the enhancement of X-ray contrast throughout the specimen’s entire vasculature 
10 min post-injection, followed by eventual renal clearance. Additionally, in mice with trans-
fected tumors, the Au NPs were shown to accumulate preferentially in the tumor, as opposed 
to healthy tissues, despite the absence of an active targeting molecule on the nanoparticle sur-
faces. After this study and its follow-up in 2006, Au NPs have been extensively researched as 
XCAs, as well as for X-ray sensitization (i.e., as agents causing radiation dose enhancement), 
photo-thermal imaging and therapy, and photo-acoustic imaging [9, 10].
The plethora of biomedical research using Au NPs has been enabled by the development of reli-
able Au NP synthesis methods, which have resulted in Au NPs with well-defined sizes and low 
size polydispersity; such Au NP formulations are now readily commercially available. However, 
while this availability has made Au NPs crucial to the demonstration of nanomaterial-based 
imaging and therapies, the use of larger Au NPs is limited by poor biological clearance, since ele-
mental gold is quite inert under physiological conditions [11–14]. The oxidative stability of ele-
mental Au presents an apparent advantage in that decomposition products are not expected to 
interfere with biochemical processes, but also results in the demonstrated disadvantage that Au 
NPs show high levels of bioaccumulation because they cannot be rapidly degraded into small, 
molecular species. This has limited several in vivo applications, including targeted X-ray imag-
ing, that would benefit from larger (i.e., >6 nm) NPs to achieve detectable radiation interactions.
While many researchers continue to work with Au NPs and look for ways to bypass this issue, 
there is a widening field of researchers who have focused their work on the development of 
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bismuth-based nanomaterials as X-ray interactive biomedical agents. A landmark publication 
demonstrating the use of bismuth-containing XCAs by Rabin et al. illustrated the potential 
of bismuth(III) sulfide nanoparticles (Bi2S3 NPs) in an in vivo mouse model [15]. The plate-shaped nanoparticles ranged from 10 to 50 nm on their longest sides, and the surfaces were 
coated with polyvinylpyrrolidone (PVP), a well-established biocompatible polymer. These 
PVP-coated Bi2S3 NPs showed a superior CT brightness compared to iopromide, a clinically used iodine-based contrast agent, and had a blood circulation half-life of 140 ± 15 min, which 
is substantially greater than the circulatory half-life of clinical iodinated XCAs. Furthermore, 
the Bi2S3 NP formulation resulted in greater contrast while administered at a lower concentra-tion and as a lower viscosity solution.
Another study of note that utilized Bi2S3 NPs as XCAs was performed by Kinsella et al. [16]. In this study, size monodisperse ~10 nm Bi2S3 NPs were prepared and surface-coated with the amphiphilic polymer 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
(amino(polyethylene glycol)) (DSPE-PEG) to produce an uncharged, hydrophilic product. 
The DSPE-PEG-coated Bi2S3 NPs were further conjugated to the LyP-1 peptide, which is a surface antigen for the p32 protein that is over-expressed in several human carcinomas. The 
accumulation of DSPE-PEG-coated Bi2S3 NPs in the tumor was observed to be increased by 70% with the addition of the LyP-1 targeting peptide, although both targeted and untargeted 
NPs produced adequate contrast to image the tumor. Ultimately, the DSPE-PEG-coated 
Bi2S3 NPs were removed by the hepatic/fecal route, as evidenced by the enhanced contrast of the intestines after a 7-day period. Overall, this publication demonstrated that: (1) even 
with a fairly small bismuth-based XCA in which the high Z bismuth payload is diluted 
by sulfur (Z = 16), contrast can be superior to that found in commercial iodinated XCAs, 
and (2) peptide-mediated active tumor targeting can increase efficacy when designing an 
intravenous agent.
Despite the successful demonstrations of Au and Bi2S3 NPs as XCAs, elemental bismuth nanopar-ticles (Bi NPs) can be argued to have significant advantages that make them potentially more 
promising as targeted XCAs. Relative to Au and Bi2S3, elemental Bi has a higher overall average atomic number, thus taking greater advantage of the general Z4 increase in X-ray attenuation. 
Additionally, elemental Bi is semi-stable with respect to oxidative dissolution, making it more 
readily biodegradable relative to Bi2S3 and Au, and therefore potentially permitting the use of larger particles. Furthermore, the degradation of elemental bismuth into bismuth ions (Bi3+) at 
physiological pH is expected to occur slowly enough to ensure that the concentration of Bi3+ in 
the blood stays below toxic levels, and the resulting Bi3+ complexes are expected to be small and 
highly biocompatible, thus presenting the opportunity for renal clearance [17, 18]. Finally, simi-
lar to many nanoparticles composed of other elements, elemental Bi shares the ability to absorb 
X-ray, visible, and near-IR radiation, which presents opportunities for additional imaging and 
treatment modalities that use longer wavelength radiation compared to X-rays.
The remainder of this chapter includes summarizing currently published synthetic strategies 
for producing aqueous Bi NPs and reviews the biomedical research that has so far explored 
these materials as XCAs, photo-therapeutic agents, and X-ray shielding materials in bio-
medical settings. Lastly, we discuss the future of Bi NPs in medical imaging and therapeutic 
technologies.
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3. Bi nanoparticles for in vivo X-ray applications
3.1. General synthesis considerations for producing medically useful Bi 
nanoparticles
While Bi NPs are a desirable platform for in vivo X-ray contrast and therapeutic applications 
owing to their dense, un-diluted payload of high Z atoms, synthesis of these materials is gener-
ally more difficult and less versatile than other high Z nanomaterials. This is most notable in 
contrast to precious metal nanoparticles of gold, silver, and platinum, which have high oxida-
tive stability. The primary difficulty in synthesizing elemental Bi NPs is oxidative decomposi-
tion, which has led to a prevalence of anaerobic synthetic strategies to prevent oxidation by O2. These methods often utilize air-sensitive or pyrophoric reagents in the reduction of a Bi3+ pre-
cursor in the presence of surface-terminating ligands. Furthermore, apolar solvents and hydro-
phobic ligands are most frequently used to avoid oxidative dissolution of the reduced Bi NPs by 
H2O, which results in products that are not water-dispersible as-prepared. Thus, further ligand coating or polymer wrapping is a common strategy to render stable, aqueous Bi NPs, although 
such strategies result in less X-ray dense particles with additional pharmacological complexity.
We have recently reviewed Bi NP synthesis methods that produce some of the lowest poly-
dispersity hydrophobic and hydrophilic Bi NP colloids at this time, with their associated size 
metrics (see Supporting information of reference [19]). However, research by our group and 
several others, has focused on the synthesis of Bi NPs in aqueous or otherwise polar condi-
tions, as well as scalable production. In general, published aqueous and polar phase syntheses 
of Bi NPs have rarely approached the colloidal stability, chemical stability, and size monodis-
persity observed in anaerobic, apolar systems. Nonetheless, a few notable synthetic methods 
have produced aqueous colloids of Bi NPs that are potentially biomedically useful, which are 
further discussed in Sections 3.2 and 3.3.
3.2. Syntheses of hydrophilic bismuth nanoparticles and demonstration as CT 
contrast agents
In a polar phase Bi NP synthesis method developed by our group, Bi3+ (from Bi(III) nitrate) 
was reduced by co-reductants morpholine borane and glucose using 1,2-propanediol as sol-
vent to result in hydrophilic Bi NPs in a single step. The resultant Bi NPs (Figure 4A) were 
observed to have an average diameter of 74 ± 14 nm by transmission electron microscopy 
(TEM), [20] and it was determined that the presence of the reducing sugar (i.e., glucose) in 
the formulation enhanced Bi NP oxidative stability in the resulting aqueous colloids. This 
synthetic method has several attractive features for biomedical usage, including a substantial 
product yield, reproducibility in the size and size distribution of the products obtained, and 
use of low cost reagents that are relatively biologically benign. Furthermore, because a poly-
meric surface stabilizer is not used, the Bi core constitutes the majority of the overall particle 
volume, representing a dense X-ray opaque payload.
We have shown that the oxidative stability of the Bi NPs prepared in this way is sensitive to 
pH, with the Bi NPs decomposing into soluble Bi3+ species at physiological pH (7.4) within 
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24 h (Figure 4B) [21]. This observation suggests a possible mechanism for biological clear-
ance, which has been a substantial clinical translation hurdle for Au NPs. The glucose-stabi-
lized Bi NP colloids were also tested in vitro, where no observable cytotoxicity was observed 
within 1 h in either a cancer or a macrophage cell line at concentrations up to 0.5 mg/mL, 
suggestive of good biocompatibility. However, at 24 h, the macrophage cell line viability 
dropped, having an LD50 of 50 μg/mL due to an observed high concentration of internalized 
Bi NPs.
In a study of quantitative contrast using a clinical CT scanner to image a non-biological 
phantom (Figure 5A), the Bi NPs produced by this method were shown to generate an 
X-ray contrast of approximately 6 HU/mM Bi (Figure 5B and C), which is greater at all 
kVp in comparison to an iodine-based standard, and more than double that of the iodine-
based standard at 140 kVp (Figure 5C). Additionally, the quantitative X-ray contrast of 
the Bi NPs was observed to be relatively insensitive to the operating voltage of the CT 
scanner, performing similarly over the range of 80–140 kVp, while the contrast of an iodin-
ated agent decreased sharply with increasing operating voltage (Figure 5C). This synthe-
sis method has since been used and further modified to produce Bi NPs that have been 
studied in vivo. [22, 23]
Li et al. adapted the synthesis method described above to demonstrate X-ray contrast in vivo 
using ~40 nm Bi NPs, which had been additionally PEG-coated to further increase biocompat-
ibility [23]. In non-biological phantom studies, these PEG-coated Bi NPs generated 3.7 times as 
much contrast as equimolar iopromide, with the measured X-ray attenuation being 60.3 HU/
(mg/mL) for the Bi NPs as compared to 16.4 HU/(mg/mL) for the iodinated agent under the 
same instrumental conditions. In vitro, no marked cytotoxicity was observed in either a can-
cer or an endothelial cell line at concentrations up to 300 μg/mL, although endocytosis was 
observed, as we also noted. In an in vivo study of tumor bearing mice, the PEG-coated Bi NPs 
were injected intravascularly and were observed to slowly accumulate in tumor tissue over the 
course of 6 hours, at which time the CT contrast was highest. This degree of non-targeted accu-
mulation in a tumor is higher than that of smaller Bi NPs and was attributed to the EPR effect. 
Figure 4. (A) TEM image of Bi NPs synthesized via reaction of morpholine borane and glucose with bismuth (III) nitrate 
in 1,2-propanediol. (B) Photographs showing pH stability of the Bi NPs 5 min (top) and 24 h (bottom) after they are 
dispersed into aqueous solution (reprinted with permission from reference [21]).
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However, this observation may in part be due to the large size of the Bi NPs, which are expected 
to have a long circulation half-life in the bloodstream prior to renal clearance.
Another synthesis method used to make Bi NPs in polar media was developed by Lei et al., 
which accomplished the reduction of Bi3+ using NaBH
4
 in a glycerol/ethanol solvent mixture and 
used polyvinylpyrollidone (PVP) to control size [24]. Since the PVP-coated Bi NPs were hydro-
philic as-prepared, no further surface modification was required for in vitro or in vivo work, 
although the addition of 5 wt% glucose to aqueous solutions of these Bi NPs was also tested. The 
resultant PVP-coated Bi NPs had an average core diameter of 2.7 ± 1.1 nm by TEM, which is nota-
bly substantially smaller compared to the Bi NPs discussed above. However, in non-biological 
phantoms, dispersions containing the ultra-small, PVP-coated Bi NPs provided approximately 2 
times greater contrast than equimolar iobitridol at 120 kVp, with the measured X-ray attenuation 
Figure 5. (A) CT image of a concentration gradient of aqueous Bi NP solutions suspended in a non-biological phantom, 
ranging from 0 to 70 mM Bi in the wells from left to right. (B) The CT attenuation of Bi NP solutions as a function of 
Bi atom concentration at various operating voltages. (C) Attenuation rates of Bi NPs, ionic bismuth, and ionic iodine 
in water at various operating voltages. Reprinted from reference [20] with copyright permission from the American 
Chemical Society. The full text of the article can be found at https://pubs.acs.org/doi/full/10.1021/cm500077z and further 
permissions related to this material should be directed to the ACS.
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being 7.1 and 3.9 HU/mM for the Bi NP and iobitridol samples, respectively. This study did not 
observe cytotoxicity in in vitro studies using up to 500 μg/mL Bi NP samples.
Lei et al. first assessed the in vivo CT contrast of the ultra-small, PVP-coated Bi NPs by intra-
tumoral injection, which showed exceptional CT contrast for the tumor. Encouraged by these 
results, the Bi NPs were administered intravenously and the bio-distribution was monitored. 
The in vivo bio-distribution studies revealed some accumulation in the liver and spleen that 
had decreased by the 24-h time point, while continued accumulation up to 24 h was observed 
in the tumor. The HU value of the tumor tissue was observed to increase slowly from 30.3 HU 
before injection to 53.8 HU at 24 h post-injection, suggesting a slow and passive accumulation 
of the nanomaterial in the tumor. The Bi NPs were apparently excreted intact within 7 days. 
Further, using a healthy specimen, a complete blood panel done following an in vivo bio-dis-
tribution assay revealed that the Bi NP-treated tissues were not significantly different relative 
to untreated specimens. The further demonstration of a therapeutic application of these ultra-
small, PVP-coated Bi NPs is discussed in Section 3.3.
A study by Yu et al. also applied ultra-small Bi NPs as both an XCA and a therapeutic agent 
[25]. In this study, Bi NPs with an average diameter of 3.6 nm were synthesized by hot injec-
tion of a solution containing Bi3+ into oleylamine, which acted as solvent, reducing agent, and 
surfactant. These initially hydrophobic Bi NPs were then made hydrophilic by coating with 
DSPE-PEG, and further functionalized by covalently attaching LyP-1, a peptide that associ-
ates with membrane proteins over-expressed in some cancerous cells. In non-biological phan-
toms, the Bi NPs generated approximately 3 times greater contrast than equimolar iohexol, 
with the measured attenuation rates being 13.8 and 4.28 HU/mM for the Bi NPs and iohexol at 
80 keV, respectively. Upon intra-tumoral injection, the Bi NP-loaded tumor was clearly visible 
by CT imaging, having a voxel intensity of >1000 HU, though this result is not extensible to 
intravenous (IV) administration. However, the bio-distribution and extent of tumor accumu-
lation after IV injection was also examined, which is discussed in Section 3.3 in the context of 
the use of the LyP-l-DSPE-PEG-coated Bi NPs as a photo-therapeutic agent.
Overall, in the studies noted above, hydrophilic Bi NPs universally outperformed iodinated XCAs 
by two- to four-fold in terms of contrast at fixed concentrations and had greater blood-circulation 
half-lives, which demonstrated promise for the use of Bi NPs as lower-dose systemic X-ray con-
trast agents. Further, the extent of passive tumor accumulation and CT contrast observed in in 
vivo studies demonstrated the possibility of using the Bi NPs to discern diseased tissues, which 
can be further enhanced by active tumor targeting, i.e., by the addition of pathology-specific 
recognition groups to the Bi NP surfaces. Additionally, bio-distribution studies of ultra-small 
(<6 nm) Bi NPs showed that they are cleared largely through the kidneys [24, 25], while larger 
Bi NPs tend to be cleared hepatically [22, 23]. In addition to their promising application in CT 
imaging, other biomedical utilities of aqueous Bi NP colloids are further discussed in Section 3.3.
3.3. Applications of Bi nanoparticles in therapeutics
As many nanomaterials have been shown to accumulate in solid tumors, the use of photon 
therapies that can excite a functional nanomaterial to produce a local and lethal effect on sur-
rounding cells is an active area of cancer research.
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One example of a photon therapy is photo-thermal therapy, which uses near infrared (NIR) 
or visible radiation to raise the local temperature of a biological tissue above 48°C, leading 
to irreversible protein denaturation and aggregation within 4–6 min [26]. NIR radiation is of 
particular utility in the field of photon therapeutics due to relatively long wavelengths that 
result in large (~10 mm) tissue penetration depths and low tissue ionization. Bi NPs broadly 
absorb both visible and NIR radiation, and afterwards vibronically relax to produce heat, 
which makes Bi NPs a candidate for use as NIR-photo-thermal therapy enhancement agents.
The above referenced study by Lei et al. demonstrated the use of Bi NPs for photo-thermal 
imaging and therapy [24]. As aqueous colloids, the NIR-to-thermal conversion efficiency of 
~3 nm PVP-coated Bi NPs was determined to be as high as 30%, which is higher than for 
other photo-thermal agents including gold nanoparticles. In a preliminary in vivo study using 
tumor-bearing mice (having both experimental and control specimens), the efficacy of Bi NPs 
as photo-thermal agents was established by IV administration of 20 mg/kg Bi NPs, which pas-
sively accumulated in the tumor of the experimental specimen over the course of 24 h. After 
24 h, both control and experimental specimens were subjected to NIR photo-therapy using 
808 nm incident light at a power of 1.3 W/cm2; the temperature of the tumors was monitored 
using an IR camera. Within 6 minutes, a temperature change of 25 ° C (to ~65 ° C) was observed 
in the tumor tissue of the Bi NP-treated specimen, while the temperature of the control speci-
men had only increased modestly (<5 ° C). In further in vivo experiments, infrared cameras 
were used to image the tumor temperature of specimens in four groups, as follows: (1) those 
not treated with Bi NPs or NIR light, (2) those treated with NIR light only, (3) those treated 
with Bi NPs (by IV injection) only, and (4) those treated with both NIR light and Bi NPs (by 
IV injection). The photo-thermal treatment, when applied, delivered 808 nm incident light at a 
power of 1.3 W/cm2 and was administered 24 h following the Bi NP injections. For specimens 
in these groups, the relative tumor volume was monitored over a period of 14 days, and it was 
observed that in the groups treated with only Bi NPs or only NIR light, the tumor volumes 
grew at the same rate as the untreated control. However, a significant growth inhibition (~10% 
the size of the other groups) was observed for the group receiving Bi NPs in combination with 
NIR therapy, which demonstrated that the local heating correlated with cancer tissue death. 
Overall, these results showed that ultra-small, passively accumulating Bi NPs could be useful 
as a photo-thermal therapy agent.
Another possible therapeutic application for Bi NPs is their use in radiation dose enhance-
ment during X- or gamma-ray treatments. Currently in the United States, over half of all can-
cer patients will receive a form of radiation therapy, typically using extremely high-energy 
photons in the MeV range. The drawback of this type of treatment is damage incurred to 
surrounding healthy tissues, which typically limits the radiation doses delivered to patients. 
Thus, there is a desire to lower the radiation dose delivered to patients while maintaining 
the efficacy of the radiation therapy for the treatment of cancers. To address this limitation, 
the development of materials that can enhance the local ionizing effects of radiation could 
make these treatments substantially more effective. So far, several nanomaterials (e.g., gold 
nanoparticles and hafnium oxide nanoparticles) have demonstrated an increase in local ion-
izing damage when used with keV radiation in small animal models, and some are currently 
in clinical trials [27–32]. However, as outlined above in the context of XCAs, bismuth has 
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a number of unique advantages for biomedical applications, which should remain true for 
their application as radiation dose enhancing nanoparticles. Furthermore, not only do Bi NPs 
attenuate X-rays far more efficiently than soft tissue, they have also been shown to produce 
photo-generated, ionizing chemical species, which can potentially be leveraged to contrib-
ute cellular damage. The mechanisms by which nanoparticles enhance cellular damage from 
radiation likely involves a multitude of reactions, and is a topic of current investigation [27].
Two groups have recently demonstrated the ability of Bi NPs to multiply local radiation ion-
ization events upon excitation by X-rays in the keV energy range. For example, Yu et al. co-
administered 3.6 nm DSPE-PEG-coated Bi NPs with a single dose of 4 Gray (Gy) radiation to 
tumor-bearing mice. [25] After 14 days, tumor growth rates of the Bi NP/radiation-treated mice-
were 33% lower than those treated by radiation alone. In the same study, Yu et al. also found 
that Bi NPs collected from the urine and feces of mice 24 h after injection had the same size and 
morphology as when they were initially injected, demonstrating that the 3.6 nm DSPE-PEG-
coated Bi NPs can be cleared but not significantly degraded in this timeframe [25]. Another 
study by Deng et al. showed similar results using 50 nm PVP-coated, untargeted Bi NPs, slow-
ing tumor growth by 43% over a 14 day period. [22] Further modification was performed on 
these Bi NPs, including conjugation of the biological-targeting group folate and encapsulation 
within red blood cell membranes. Here, it should be noted that nanoparticles with folate surface 
ligands have previously shown increased accumulation in multiple cancerous tissues types that 
overexpress folate receptors. The authors observed that when the RBC-modified, folate-targeted 
Bi NPs were used, tumor growth rates were reduced by more than 50% compared to radiation 
alone, and mouse survival rates over 36 days increased from 0 to 60%.
Overall, the studies of Bi NPs as photo-therapuetic agents have shown that a synergistic com-
bination of NIR or X-ray radiation with intravascularly administered Bi NPs can significantly 
impact tumor growth rates. In addition, several of these recent in vivo studies have included 
monitoring for possible tissue damage or changes in blood serum concentrations after admin-
istration of Bi NPs and radiation [22–25]. These studies have revealed that while tumor tissue 
samples tend to show damage from the co-administration of Bi NPs and radiation, tissues in 
the heart, lungs, spleen, liver, and kidneys have all been found to remain undamaged. Thus, 
the use of Bi NPs in NIR and X-ray photo-therapies may prove useful for increasing the effi-
cacy of these procedures in cancer treatments. Finally, while we have discussed the use of Bi 
NPs as both imaging and therapeutic agents in the former sections, we end this chapter by 
discussing the use of Bi nano- and microparticles in macroscopic radiation-attenuating tools, 
such as personal protective equipment and imaging guides.
4. Bi nano- and microparticles for X-ray shielding in medical 
applications
4.1. Current status of X-ray shielding materials
There is a substantial call from the medical community for improved radiation shielding gar-
ments for medical personnel who regularly work in proximity to high-energy radiation [33]. 
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Increased awareness of the harmful stochastic effects of radiation exposure, coupled with an 
increase in the number of medical procedures (primarily X-ray fluoroscopy) and the increased 
X-ray voltages required for imaging larger patients, have raised concerns about accumulated 
radiation exposure to medical personnel [34, 35]. Research has shown that medical person-
nel who regularly work with high-energy radiation are particularly susceptible to, and have 
increased incidences of, specific types of cancer [36]. Because of the ubiquitous use of ionizing 
radiation in medicine, specialty garments, tools, and devices have been developed, both for 
protection against the harmful effects of radiation, as well as for use with radiation imaging.
In radiation imaging, such tools include catheters that contain platinum wires for use with 
fluoroscopic imaging and gold fiducial markers that are surgically embedded in a patient to 
provide guides in CT imaging and therapeutic radiation delivery [37]. In personal protec-
tive equipment, radiation-interacting (or shielding) materials include specialized rooms with 
lead-lined walls, leaded glass viewing areas, and lead-based radiation protective garments. 
More recently, specialized drapes and blankets have become available.
Personal radiation shielding garments have historically been composed of lead salts (e.g., 
Pb(II)SO
4
) embedded into a plastic matrix to form a wearable composite material. This design 
results in a hard, brittle composite containing a large percentage of lead salt (>60%) by weight. 
This composite is then encased between heavy vinyl sheets to keep the lead from contacting 
the wearer. The weight burden from lead is roughly 50% of the overall garment weight, with 
the plastic casing composing the remainder. Recently the isolation of lead dust by this design 
has caused lead aprons to become a suspected source of lead poisoning in medical settings 
[38]. Lead aprons are the most commonly encountered garment of this type and by design 
these are worn as an X-ray shield to protect the torso and upper legs, leaving the head, neck, 
and arms exposed to radiation. Garments designed to shield additional areas, such as thyroid, 
gonads and breasts, and less commonly, the head and hands, are also sparingly used in medi-
cal environments, but are extremely bulky and cumbersome.
Lead is heavy, toxic, and environmentally damaging, which makes it a good candidate for 
replacement by alternative elements that can provide good X-ray shielding. Lightweight shield-
ing materials containing lower atomic number elements have been developed and are marketed 
specifically to address the weight burden issue that lead-based garments suffer from. In these 
products, the lead salt is replaced with a mixture of salts of lighter elements, including barium, 
tin, tungsten, and some lanthanoids. These garments are tested and marketed as having a “lead 
shielding equivalent” at a specific tested X-ray voltage. However, when tested over a range of 
X-ray voltages (kVp), other than the voltage they were optimized for, they can show an inad-
equate radiation attenuation. [39] X-ray attenuation is reported in “mm of lead” and as a kVp is 
not specified for this testing, this has enabled manufacturers to report misleading shielding data 
and has raised concern for medical personnel who rely on these garments for protection [40].
For high performance X-ray contrast devices, such as catheters or other medical devices that 
are surgically inserted, tungsten particles or platinum wires are generally utilized. Use of these 
elements also has drawbacks, including difficulty in manufacturing and processing. Tungsten 
is extremely hard, requiring specialized equipment to process, while platinum is extremely 
expensive (>$13,000/lb) and is thus limited to use in small devices, such as catheter tips.
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Bismuth is an excellent candidate for lead replacement in garments and platinum and tung-
sten replacement in surgical devices. Relative to lead, it has a similar or higher X-ray attenua-
tion cross-section, but is non-toxic. Bismuth has a lower melting point relative to tungsten (272 
vs. 3422°C) and is much softer (2.2 vs. 7.5 Mohs hardness), making it much easier to machine. 
The challenge with adapting bismuth for use in shielding garments has historically been the 
price of raw material. Though much cheaper than platinum and somewhat less expensive 
than tungsten (approximately $20 per pound), bismuth prices have fluctuated widely over the 
past decades from $3 to $30 per pound, while lead has historically been roughly $1 per pound. 
Incorporating bismuth particles into medical devices has been explored by device manufac-
turers, but the low oxidative stability of bismuth during processing has limited manufacture 
adaptation. However, we have recently developed a method for the production of surface-
stabilized Bi nano- and microparticles that are easily polymer-dispersed for use in medical 
devices and protective garments, which are described in Section 4.2 [41].
4.2. Fabrication of Bi nano- and micro-composites for X-ray shielding applications
We have recently developed a method to produce microscopic, surface-passivated bismuth par-
ticles for the creation of plastic X-ray opaque composites [41]. To produce the surface-passivated, 
micron-sized bismuth material we utilize high-energy ball milling of bismuth ingot in various 
organic solvents or other surface coordinating ligands. The organic passivants coat the freshly 
fractured Bi crystallites, thus minimizing surface oxide formation. Particles produced are of a 
broad range in size (from a few hundred micrometers, down to the nanometer scale) and can 
be size selected for a specific application. Excess particles are easily melted on the bench top 
and the bismuth can be recovered and recycled though the milling and passivating process. 
Furthermore, the wide choice of organic solvent also permits tuning the particle hydrophilicity 
and chemical functionality to permit dispersal of the micrometer scale bismuth domains into a 
variety of plastics. As examples, we have produced hydrophilic bismuth microparticles by mill-
ing in the presence of dihydroxyacetone (DHA) and 1,2-propane diol, and hydrophobic bismuth 
microparticles by milling in the presence of in 1-pentene, or styrene, and toluene. The resulting 
bismuth microparticles suspended in their milling solvents are generally collected by centrifu-
gation, washed with an appropriate solvent, dried, ground to a fine powder and sieved to col-
lect particles in a narrow size range. Such organic-passivated, size-selected particles can then be 
mixed into molten or uncured polymers such as silicone, polyurethane, polystyrene, and latex to 
form X-ray opaque polymer composites Figure 6(A-C). The weight percent of the micron-sized 
radiopaque filler in these composites can be readily calculated and varied over a wide range. We 
observed that the bismuth microparticles embedded in these composites do not undergo sub-
stantive oxidative decomposition, nor do they aggregate within the polymeric matrix.
We tested one possible application of such composite materials for the fabrication of radiopaque 
surgical sponge markers, which are commonly used in surgery to avoid retention of foreign 
objects [21]. In doing so, we prepared polyurethane composites containing 20, 40, 60, and 85 
wt% of our bismuth micron material and compared them to a commercial sponge marker. 
The commercial sponge marker was produced by Medline Industries and is reported to be a 
polymer-salt composite of polyvinylchloride containing between 60 and 83% Ba(II)SO
4
 as the 
radiopaque filler. Our composites were prepared by mixing uncured liquid polyurethane with 
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dried, sieved DHA-coated bismuth microparticles, and the resulting mixture was molded using 
Teflon plates to produce a “ribbon” of similar thickness to the commercial sponge marker.
To compare attenuation of the commercially available surgical sponge marker to the bismuth 
composite markers, X-ray attenuation measurements were performed by an external analytical 
laboratory across a range of medically relevant incident photon energies. The composite sam-
ples tested were 0.56, 0.55, 0.51 and 0.64 mm thick for the Medline, 40, 60 and 85% by weight 
bismuth markers, respectively. The attenuation of the commercial composite only exceeded the 
attenuation of the 20% bismuth composite across all energies, and the 40% bismuth composite at 
incident photon energies below 80 kVp. However, superior attenuation across all voltages was 
observed for the 60 and 85% bismuth composites as compared to the commercial composite. 
For the 85% bismuth composite, the percent X-ray attenuation was nearly 100% at 60 kVp, more 
than double that of the commercial marker. Further, the 85% bismuth marker was determined to 
have a lead equivalent X-ray attenuation of 0.21 mm, which would indicate that a 1.2 mm thick 
sheet of the 85% bismuth composite material would provide similar radiation protection to 
the lead aprons commonly used in medical facilities (0.5 mm lead equivalent attenuation) [38]. 
While this is thicker than a sheet of solid lead, the low toxicity of bismuth means that the 
Figure 6. (A) Components of a composite X-ray shielding material. (B) SEM of polymer/filler composite materials with 
varied mass percent of filler (bismuth microparticles or BaSO
4
). (C) X-ray attenuation of bismuth microparticle- and 
BaSO
4
-containing X-ray shielding materials at various operating voltages (reprinted with permission from reference [21]).
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shielding material can be placed directly against the skin, and will not require thick protective 
layers around the functional material. As a substantial portion of the weight burden from lead 
shielding garments is a result of the vinyl sheeting required to isolate the lead, we estimate that 
a bismuth particulate shielding garment would be roughly half the weight of a lead garment.
We expect the radiopaque bismuth micromaterial filler we have produced will find use in a 
variety of thin, flexible plastic composites that can be molded into 3D shapes (such as hats, 
gloves, or long-sleeved shirts) to provide an improved form factor relative to current tech-
nologies. Fabrication of thin, flexible X-ray opaque composite materials should enable better 
engineering of shielding garments, specifically in regards to the weight burden and flexibility 
restriction on the wearer.
5. Summary and prospectus for the future of bismuth nano- and 
microparticles in biomedical X-ray applications
New synthetic methods for producing hydrophilic Bi NPs in the 2–100 nm size range are 
increasingly reported. As interest in adapting new nanomaterials for biomedical applica-
tions continues to grow, it is expected these materials will be further explored and find new 
niche applications or facilitate development of new technologies in nanomedicine. Bismuth 
nanoparticles have demonstrated superior X-ray contrast by CT imaging, which exceeds the 
clinical standard of iodinated X-ray contrast media by 2–4-fold. This may permit the use of 
systemically administered Bi NPs as lower dose, lower viscosity, and lower toxicity contrast 
agents. The passive accumulation of untargeted Bi NPs in tumors has demonstrated a high 
tumor CT signal and has been shown to provide a means of sensitizing cancer tissues to 
local radiation damage using NIR and X-ray photo-therapies. Additionally, the replacement 
of lead in personal shielding garments has the potential for development of new and more 
practical personal protective equipment. The high biocompatibility, low cost, and exceptional 
X-ray attenuation of bismuth make this unique element a rising star in the application of new 
technologies in radiation medicine.
The future of hydrophilic Bi NP contrast and therapeutic agents will likely see more active 
biological targeting studies, with the goal of using Bi NPs to selectively and specifically seek 
out known biochemical markers of disease. The specific biomarkers of disease that are the 
target of molecular imaging and therapy are known to be present at low concentrations (10−9 to 
10−10 M), necessitating that the imaging modality used is capable of detecting imaging agents at 
similarly low concentrations [42]. Since the limit of detection of CT imaging is high, this would 
necessitate the delivery of a large number of X-ray attenuating atoms to a highly localized area, 
which may be possible with pathology-targeted, high Z nanoparticles. To estimate how many 
Bi NPs this would require, achieving a 100 mM concentration of Bi in a 1 mm3 volume would 
require 10−7 mol of Bi, which for uniform 150 nm Bi NPs is approximately 109 Bi NPs. Given 
a reasonable tumor cell density of 106–107 cells/mm3, 1–10 Bi NPs per tumor cell would be 
needed [43]. Further bio-distribution studies of IV injected pathology-targeted Bi NPs would 
be needed to determine whether this is possible, and to establish the actual limit of detection.
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In the majority of the studies reviewed above, favorable in vitro and in vivo biocompatibility was 
observed for hydrophilic Bi NPs. However, so far, only ultra-small Bi NPs have a predictable 
and practical biological clearance mechanism via renal filtration, while the larger Bi NPs that 
could be most useful as targeted imaging agents are unpredictably endocytosed. Endocytosis 
of larger Bi NPs may be useful if they are selectively uptaken by disease tissue and used in 
a photo-dynamic therapies, but this would be limiting in a targeted imaging application. 
Consequently, further research may involve the encapsulation of ultra-small Bi NPs into larger 
structures, such as blood cells, liposomes, polymeric aggregates and other nano-sized drug-
delivery motifs. The goal would be to maximize the overall aggregate signal in a small volume 
host, while permitting renal clearance of the payload after release from the host. Alternatively, 
the use of large Bi NPs may be achievable if surface stabilization strategies or appropriate for-
mulations could be designed to control the rate of oxidative dissolution of the Bi NPs.
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